Title | AhR activation increases IL-2 production by alloreactive CD4 T cells initiating the differentiation of mucosal-homing Tim3 Lag3 Tr1 cells. |
Publication Type | Journal Article |
Year of Publication | 2017 |
Authors | Ehrlich, AK, Pennington, JM, Tilton, S, Wang, X, Marshall, NB, Rohlman, D, Funatake, C, Punj, S, O'Donnell, EF, Yu, Z, Kolluri, S, Kerkvliet, NI |
Journal | Eur J Immunol |
Volume | 47 |
Issue | 11 |
Pagination | 1989-2001 |
Date Published | 2017 11 |
ISSN | 1521-4141 |
Keywords | Allografts, Animals, CD4-Positive T-Lymphocytes, Cell Differentiation, Cell Movement, Interleukin-2, Intestinal Mucosa, Lymphocyte Activation, Mice, Mice, Inbred C57BL, Mice, Transgenic, Receptors, Aryl Hydrocarbon, T-Lymphocytes, Regulatory |
Abstract | Activation of the aryl hydrocarbon receptor (AhR) by immunosuppressive ligands promotes the development of regulatory T (Treg) cells. Although AhR-induced Foxp3 Treg cells have been well studied, much less is known about the development and fate of AhR-induced Type 1 Treg (AhR-Tr1) cells. In the current study, we identified the unique transcriptional and functional changes in murine CD4 T cells that accompany the differentiation of AhR-Tr1 cells during the CD4 T-cell-dependent phase of an allospecific cytotoxic T lymphocyte (allo-CTL) response. AhR activation increased the expression of genes involved in T-cell activation, immune regulation and chemotaxis, as well as a global downregulation of genes involved in cell cycling. Increased IL-2 production was responsible for the early AhR-Tr1 activation phenotype previously characterized as CD25 CTLA4 GITR on day 2. The AhR-Tr1 phenotype was further defined by the coexpression of the immunoregulatory receptors Lag3 and Tim3 and non-overlapping expression of CCR4 and CCR9. Consistent with the increased expression of CCR9, real-time imaging showed enhanced migration of AhR-Tr1 cells to the lamina propria of the small intestine and colon. The discovery of mucosal imprinting of AhR-Tr1 cells provides an additional mechanism by which therapeutic AhR ligands can control immunopathology. |
DOI | 10.1002/eji.201747121 |
Alternate Journal | Eur. J. Immunol. |
PubMed ID | 28833046 |
PubMed Central ID | PMC5927372 |
Grant List | P30 ES000210 / ES / NIEHS NIH HHS / United States R01 ES016651 / ES / NIEHS NIH HHS / United States T32 ES007060 / ES / NIEHS NIH HHS / United States P01ES00210 / ES / NIEHS NIH HHS / United States |